Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication

Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

Customer Contact Center

1-888-PLMZYME (756-9963)

Pulmozyme Access Solutions®

Understanding Cystic Fibrosis

You fight it every day—be sure to fight it in every way.

Cystic fibrosis (CF) is a complicated genetic disease that causes your body to produce extra-thick, sticky mucus. If you or your loved one is fighting this disease, they may require medicines as part of their treatment routine. Because not all medicines work the same or address the same symptoms, a combination of medications may be needed.

Pulmozyme is a commonly prescribed CF medicine that uniquely targets one of the causes for such mucus: extracellular DNA. In order to understand how Pulmozyme targets extracellular DNA, picture how a pair of scissors can be used to cut something into smaller pieces. Similarly, laboratory studies have shown that Pulmozyme cuts apart extracellular DNA by acting like an enzyme* found naturally in the body.

Your doctor and CF Care Team want you to have treatment that keeps you as healthy as possible. Being open about your questions or concerns can help you and your doctor make the right treatment decisions for your fight against CF. Continue reading through the next sections to find out more about how Pulmozyme may help you in your fight against CF.

For more information about cystic fibrosis, visit the Cystic Fibrosis Foundation at www.cff.org

* Enzymes are proteins created by the body to help speed up chemical reactions (such as the breakdown of molecules).